Yohimbine is the only commercially available compound that selectively antagonizes the α2-adrenergic receptor at therapeutic doses. Its effect on belly-specific lipolysis is mechanism-driven and depot-selective, and its position in the Riverclear protocol is almost entirely about what it can do that nothing else can.

Mechanism

Competitive antagonism at α2-adrenergic receptors, with moderate selectivity over α1 and β receptors at therapeutic doses. By occupying α2 receptors on adipocyte surfaces, yohimbine prevents endogenous norepinephrine from binding and triggering the inhibitory G-protein cascade. The result is removal of the brake on adenylyl cyclase, allowing cAMP elevation and lipolysis to proceed.

Because abdominal subcutaneous and visceral adipose have far higher α2 receptor density than gluteofemoral adipose, yohimbine's lipolytic effect is regionally selective — it primarily mobilizes belly fat. This is the only commercially available pharmacological intervention that produces this regional selectivity at a clinically meaningful effect size.

The compound's other α-adrenergic effects produce its side-effect profile: mild α1 antagonism contributes to vasoconstrictive bypass, mild central nervous system stimulation produces alertness and at higher doses anxiety, mild adrenergic activation can produce blood pressure elevation and tachycardia.

Dose

0.1 to 0.2 mg per kilogram of body weight, taken in the fasted state. For most adults this falls in the 5 to 16 mg range. Start at 3 mg for the first dose ever taken; titrate up over five to seven days only if the lower dose is well-tolerated.

Most users converge on 5 to 10 mg as their working dose. Doses above 20 mg in a single bolus are not recommended and provide no additional fat-loss benefit while substantially elevating the side-effect profile.

The compound has a short half-life (approximately 36 minutes) and clears within about three hours. Once-daily dosing in the morning is the standard pattern; second doses produce diminishing returns and accumulate side effects.

The fasted-state requirement

Yohimbine's lipolytic effect is entirely dependent on the fasted state. Insulin from any meal eaten in the prior four hours overrides the α2 antagonism through downstream regulation of hormone-sensitive lipase, and the compound's effect collapses to noise. The Mobilize window is therefore strictly fasted, with the compound taken on an empty stomach 30 minutes after waking.

Side effects

Common at therapeutic doses: mild anxiety, jitteriness, transient hypertension, increased perception of cardiac contraction. Less common but more serious: sustained tachycardia, panic episodes, and in pre-existing cardiovascular disease, hypertensive crisis.

Users new to yohimbine should test the compound on a non-cardio day first to assess individual tolerance. Cardiovascular response varies dramatically across individuals; some people tolerate 10 mg without notable effect while others have palpitations at 5 mg.

Contraindications

Hard contraindications, no exceptions:

The MAOI interaction is particularly dangerous and can be fatal. Users on stimulant medications (ADHD treatment, certain weight-loss prescriptions) should not add yohimbine without medical supervision, and in most cases should omit yohimbine from the Mobilize stack entirely.

For users in any of the contraindicated categories, the Mobilize window runs without yohimbine, relying on caffeine, EGCG, forskolin, and L-carnitine. Effect is reduced but not zero.

Where it appears in the protocol

Primary: Mobilize window, daily during the intensive phase. Cycling: cycle off for two weeks at week 3 of the protocol; resume at reduced frequency (three times per week) in the maintenance phase if continued use is desired.